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Psoriasis Epidemiology: The Interplay
of Genes and the Environment
Monica Enamandram1 and Alexa B. Kimball1
Psoriasis is a common chronic dermatological disease whose prevalence varies
among different populations worldwide. In epidemiological studies, the factors
that potentially account for this variability include climate, genetic susceptibility,
and environmental antigen exposure. In this issue, Parisi et al. performed a
systematic review to explore the global prevalence and incidence of psoriasis.
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In this issue, Parisi et al. (2012)
comment on the worldwide prevalence
and incidence of psoriasis, which is
thought to affect B2–3% of the
world’s population (Lima et al., 2012).
On the basis of a systematic review of
53 population-based studies, the authors
stratified the rates of psoriasis by age,
gender, and geographic location.
Psoriasis was found to be more comm-
on in adults, and studies suggested
increasing incidence with age up to 39
years. Global studies showed a second
increase in psoriasis incidence during
the sixth and seventh decades; how-
ever, these rates appeared to decline
toward the end of life. No evi-
dence clearly supported gender-based
differences in prevalence. The authors
also remarked on the variability in
psoriasis prevalence across different
geographic locations.
Some of the differences in population
estimates evidenced in this work no
doubt reflect the limitations of our cur-
rent epidemiologic tools to measure the
prevalence of skin disease across popu-
lations accurately. However, several
real differences are plausible and
may be because of environmental mod-
ulation, genetics, historical migration
patterns and evolutionary pressures,
and regional variations in antigen
exposure.
Environmental factors and psoriasis
prevalence
The well-recognized relationship
between UV radiation exposure and
clinical improvement in many cases of
psoriasis has sparked further investiga-
tion into how geographic location could
influence the epidemiology of psoriasis.
To date, epidemiological studies of
psoriasis have demonstrated variable
prevalence rates across the globe.
Parisi et al. (2012) suggest that the
distribution of psoriasis ranges from
0.73 to 2.9% in Europe and from 0.7
to 2.6% in the United States. This
contrasts with the rates observed in
Latin Americans, Indians, Africans
(Egypt and Tanzania), and Asians
(China, Sri Lanka, Taiwan) in this
study, which varied from no cases
detected to o0.5% of the population
(Parisi et al., 2012).
Natural sunlight has been used for
decades to treat psoriasis. A primary
initiating factor in the pathogenesis of
this condition is believed to be hyper-
stimulation of antigen-presenting cells
and autoreactive dermal T cells. World-
wide, establishing the correlation
between levels of ambient UV radiation
and rates of psoriasis presents an epide-
miological challenge. Studies to date
have been attempted in the context of
other autoimmune diseases, namely by
Okada et al. (2003), for autoimmune
myositis. In their analysis, surface UV
radiation was the environmental factor
that most strongly correlated with the
relative proportion of dermatomyositis
and related autoantibodies at the
population level. This relationship is
biologically compelling, as UVA radia-
tion and UVB radiation have been
shown to decrease antigen presentation
and alloactivation, resulting in dimini-
shed T-cell responses. UV radiation is
also known to induce regulatory T cells
with suppressive activities (Okada et al.,
2003). Thus, the efficacy of sunlight and
phototherapy in clearing psoriasis is likely
due to immunomodulatory mechanisms,
which theoretically may vary according
to geographical UV distribution.
However, in a previous study of 22
population-based surveys, case–control
studies, and reviews, the relationship
between psoriasis prevalence and abso-
lute latitude was explored. Prevalence
rates ranged from 0% (in Samoa, aver-
age absolute latitude 13.35) to 3.3% (in
Tanzania, average absolute latitude 6).
In the Arctic Kasach’ye (average abso-
lute latitude 66.03), an exceptional pre-
valence of 11.8% was reported as well.
From the global regional data, the med-
ian psoriasis prevalence rate was
1.43%, and no meaningful correlation
between absolute latitude and disease
prevalence was demonstrated (Jacobson
et al., 2011).
Despite these findings, other environ-
mental factors may account for the
observed regional variations in psoriasis
prevalence and its potential correlation
with distance from the equator. Ambient
sunlight has the potential to mitigate the
population rates of UV-responsive skin
disease. Regionally, therefore, the
degree of outdoor exposure and the
number of sunny days in a particular
locale may influence the prevalence of
psoriasis (Jacobson et al., 2011).
Furthermore, photoprotection habits,
altitude, and ground reflection of UV
light may also account for differences in
the average UV exposure of patients.
According to the World Health
Organization (WHO), at higher alti-
tudes there is a 10 to 12% increase in
UV fluences. Furthermore, solar UV
radiation is reflected to varying degrees
by different surfaces; snow may reflect
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up to 80% of UV radiation, compared
with 15% reflected by dry beach
sand (WHO, 2002). Ultimately, it is
thus plausible that several interacting
environmental factors may contribute
to the overall geographic distribution
and prevalence of psoriasis worldwide.
Global variation in genetic
predisposition to psoriasis
Psoriasis is a complex and multifactorial
disease, with its genetic basis demon-
strated in linkage and genome-wide
association studies. The concordance
of psoriasis in twin studies also suggests
a familial basis for the disorder. A 35–
72% concordance has been demon-
strated in monozygotic twins, compared
with a 12–30% concordance in dizygo-
tic twins. Furthermore, among the con-
cordant twin pairs, psoriasis is
characterized by similar age of onset,
disease distribution, severity, and clin-
ical course (Oka et al., 2012). A strong
genetic association between the HLA-
Cw6 allele and psoriasis has been
established in various races, although
this individual locus likely explains only
part of the overall heritability of
psoriasis. Through genetic linkage
studies, a number of additional psori-
asis-susceptibility regions have been
mapped, including PSORS1 (gene
candidate HLA-C) on 6q21.33,
PSORS2 (gene candidates SLC9A3R1
and RAPTOR) on 17q25, PSORS4
(gene candidates LCE3B and LCE3C)
on 1q21, and PSORS5 (gene candidate
SLC12A8) on 3q21. None of these loci,
however, demonstrated predis-
position to psoriasis with a large effect
other than PSORS1 (Oka et al., 2012).
A number of genome-wide associa-
tion studies of psoriasis have been per-
formed in recent years. The results of
these studies have identified 24 genetic
loci associated with psoriasis, many of
which are thought to involve underlying
mechanisms of psoriasis pathogenesis.
Identified genetic variants involve geno-
mic regions potentially related to skin
barrier function, IL-23 signaling, NF-kB
and IFN signaling, and IL-17 cell
responses. To date, however, specific
susceptibility genes have yet to be iden-
tified. Many of the genetic variants that
demonstrate association with psoriasis
are located in intergenic (intronic)
regions. As such, further investigation
is required to identify clinically signifi-






Although the specific genetic
mechanisms underlying psoriasis are
not yet fully elucidated, global psoriasis
rates suggest significant heritability.
Some of the geographical variation in
psoriasis prevalence may be due to
distinct genetic predispositions of popu-
lations, as well as historical and current
migration patterns. In Northern Europe,
psoriasis affects B2–3% of the popula-
tion, representing a somewhat high
overall prevalence (McFadden et al.,
2009). In the US study, a similar rate
of psoriasis was observed among
Caucasians: 2.5% of Caucasian
patients reported physician-diagnosed
disease, whereas African-American
patients reported disease prevalence at
1.3% (Gelfand et al., 2005). In the
United States, most African Americans
are originally of West African heritage,
where the prevalence of psoriasis is low,
reported to be o1% in a number
of nations, namely Ghana, Nigeria,
Mali, and Angola (Chandran and
Raychaudhuri, 2010). In light of his-
torical migration pattern, the fact that
the prevalence of psoriasis in African
Americans remains low suggests an
overall reduced genetic predisposition
in this population.
In the study by Parisi et al. (2012), a
similar phenomenon was observed with
respect to the prevalence of psoriasis in
Australian adults. Estimates of preva-
lence ranged from 2.30 to 6.6% in
three Australian studies (Parisi et al.,
2012). Although this may reflect a
number of contributory factors, it is
possible that the elevated psoriasis prev-
alence is partly because of European
migration and resultant elevations in
population-level genetic predisposition.
Ultimately, it is thus possible that the
original rates of psoriasis are retained in
populations with a history of migration,
which suggests a predominantly genetic,
rather than geographic, basis to disease
susceptibility.
The role of environmental antigen
exposure in psoriasis pathogenesis
When examining the global psoriasis
prevalence and incidence, patterns of
antigen exposure are important to con-
sider, as they may also confer increased
disease susceptibility in genetically pre-
disposed populations. For example,
Streptococcal infections are historically
considered a preceding insult that can
precipitate the onset of guttate psoriasis.
These skin lesions appear typically
within 2 weeks of infection onset and
remain present for several weeks, some-
times progressing to chronic plaque
psoriasis (McFadden et al., 2009). In
scarlet fever as well, streptococcal
pyrogenic exotoxins are thought to func-
tion as superantigens, binding directly to
major histocompatibility complex (MHC)
class II molecules. In turn, the resultant
widespread activation of naive T cells
appears to lead to systemic proinflam-
matory cytokine release.
In such superantigen-mediated dis-
ease, T-cell activation is thought to
occur through the Vb TCR region. Pre-
vious studies have established a com-
pelling link between guttate psoriasis
and a superantigen-driven immunologi-
cal response. For example, skin biopsies
in patients with acute guttate psoriasis
demonstrate increased expansion of Vb
2þ T cells compared with controls,
supporting the concept that streptococci
may at least partly stimulate acute gut-
tate psoriasis (McFadden et al., 2009).
Similarly, peripheral blood samples
from patients with guttate psoriasis
have shown increased expansion of
Vb-restricted cutaneous lymphocyte
associated antigen–positive skin-homing
lymphocytes (Davison et al., 2011).
In chronic plaque psoriasis, T cell–
mediated autoimmunity may partly be
due to immunological cross-reactions
between streptococcal and skin anti-
gens. The Vb analysis of peripheral
blood T lymphocytes, however, does
not support a similar role of superanti-
gen-mediated immune hyperstimulation
as demonstrated in acute guttate psor-
iasis (Davison et al., 2011). Both
streptococcal infection and psoriasis
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share pathways of T-cell and innate
immune activation, and therefore the
role of streptococci in plaque psoriasis
ultimately requires further elucidation.
Despite the lack of established caus-
ality between chronic plaque psoriasis
and streptococcal infection, the theore-
tical link between disease pathogenesis
and preceding antigen exposure is pro-
mising. Globally, populations are
exposed to a heterogeneous multitude
of environmental and infectious anti-
gens. Regional differences in antigen
exposure may thus account for some of
the variation observed in the incidence
and prevalence of psoriasis, and it may
be that the same genes that now lead to
psoriasis also confer or in the past
conferred a selective advantage against
skin infection.
Concluding remarks
As Parisi et al. (2012) indicate in this
issue, a number of narrative reviews of the
epidemiology of psoriasis have been
published, but the prevalence and
incidence of psoriasis worldwide is not
yet well characterized. Limitations of this
study stem from substantial methodo-
logical differences among the cited
studies. In addition, as acknowledged by
the authors, variability in the identification
of psoriasis cases and prevalence mea-
sures (point, period, or lifetime) have also
limited this analysis because of hetero-
geneity in data collection methods.
Nevertheless, global epidemiological
studies have paved the way for greater
appreciation of the disease burden of
psoriasis and have pointed out the great
need to improve our skin disease epide-
miology on both national and global
basis. With further epidemiological
characterization, future investigation
may ultimately shed light on additional
nuances of the pathogenesis of this
common but complex disorder.
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Dacarbazine in Melanoma: From a
Chemotherapeutic Drug to
an Immunomodulating Agent
Selma Ugurel1,2, Annette Paschen3 and Ju¨rgen C. Becker2
Chemotherapeutic drugs are clinically used to treat cancer because of their
cytotoxic activities against tumor cells. Recently, however, evidence is accumu-
lating—including the report of Hervieu et al. (2012) in the current issue of The
Journal of Investigative Dermatology—indicating that at least some of these drugs
have broader activities and that they should also be considered immuno-
modulatory agents. Indeed, Hervieu demonstrates that dacarbazine (DTIC)
exerts immunostimulatory effects by inducing local activation of natural killer
(NK) and T cells, suggesting that upon treatment with DTIC, the tumor participates
in the initiation of an immune response: (i) DTIC treatment elicits the expression
of ligands of the immunoreceptor NKG2D on melanoma cells; (ii) engagement of
the ligands by NKG2D on NK cells leads to their activation, allowing enhanced
tumor-cell killing and the release of IFN-g; and (iii) IFN-g in turn upregulates
major histocompatibility complex class I expression on tumor cells, which favors
their recognition by cytotoxic CD8þ T lymphocytes (CTLs).
Journal of Investigative Dermatology (2013) 133, 289–292. doi:10.1038/jid.2012.341
For decades, chemotherapy with dacarba-
zine (DTIC) has served as the therapeutic
standard in patients with inoperable
metastatic melanoma, despite the fact
that a survival benefit by this drug has
never been demonstrated in clinical trials,
making its effectiveness still a matter
of doubt. Nevertheless, until recently,
other treatment regimens tested against
DTIC in clinical phase-III trials failed
to demonstrate superiority in patient
survival. Fortunately, however, this has
See related article on pg 499
1Department of Dermatology, University of Wu¨rzburg, Wu¨rzburg, Germany; 2Division of General
Dermatology, Medical University of Graz, Graz, Austria and 3Department of Dermatology, University of
Essen, Essen, Germany
Correspondence: Ju¨rgen C. Becker, Division of General Dermatology, Medical University of Graz,
Auenbruggerplatz 8, Graz 8036, Austria. E-mail: juergen.becker@medunigraz.at
COMMENTARY
www.jidonline.org 289
